Zobrazeno 1 - 10
of 2 448
pro vyhledávání: '"SGLT-2"'
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-13 (2024)
Abstract Background Sodium glucose cotransporter-2 (SGLT-2) inhibitors are known to reduce hospitalization and cardiovascular mortality in various heart failure (HF) populations, potentially through enhanced excretion of water and sodium. However, th
Externí odkaz:
https://doaj.org/article/9b2853359b6e4639bec1a8252fd3598e
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-6 (2024)
Abstract Background Sodium-glucose transporter-2 inhibitors (SGLT-2i) are recommended for use in patients with type 2 diabetes comorbid atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Limited reports are currently av
Externí odkaz:
https://doaj.org/article/928df423629a462696609b75dbabdb81
Autor:
Mohamed E. A. Mostafa, Tariq Alrasheed
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundType 2 diabetes mellitus (T2DM) is linked to a heightened likelihood of experiencing fractures. It is crucial to ascertain whether medications used to lower blood sugar levels can elevate the risk of fractures. We aimed to investigate and c
Externí odkaz:
https://doaj.org/article/47f21d418b0641ccab2fd0fcc4196bbf
Autor:
Paulina Bednarczyk, Izabella Chodak, Weronika Chodak, Magdalena Czyczerska, Martyna Klimek, Sebastian Lechowski
Publikováno v:
Quality in Sport, Vol 23 (2024)
Introduction. Cardiovascular disease is a leading cause of morbidity and mortality among patients with type 2 diabetes mellitus. The emergence of flozins, a class of sodium-glucose co-transporter-2 inhibitors, has introduced a novel therapeutic avenu
Externí odkaz:
https://doaj.org/article/4d404768414f4482b87c26e2065d37e0
Autor:
Joanna Winciorek, Piotr Cyran, Anna Jaroszyńska, Filip Jaroszyński, Joanna Kowal, Jan Paleczny, Robert Parobczak, Paweł Jakub Połujański, Adrianna Marta Wiśniewska
Publikováno v:
Journal of Education, Health and Sport, Vol 68 (2024)
AIM: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained significant importance in the treatment of type 2 diabetes mellitus. One of the adverse effects while using SGLT-2 inhibitors is euglycemic ketoacidosis (euDKA) - acute life-threaten
Externí odkaz:
https://doaj.org/article/958a626ec5364b9598586606e4c34a7b
Publikováno v:
Clinical Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Key Clinical Message High‐dose acarbose may increase the risk of diabetic ketosis/diabetic ketoacidosis in Asian patients on sodium‐glucose cotransporter‐2 inhibitors. Healthcare providers and patients should be cautious to avoid this combinati
Externí odkaz:
https://doaj.org/article/f82e647bdd0e40918e392880c54f0f60
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundThe escalating global economic burden of ischemic stroke poses a significant public health challenge amid global aging trends. The broad therapeutic efficacy of new antidiabetic drugs may offer new options in the prevention and treatment of
Externí odkaz:
https://doaj.org/article/098676a1cb96438992299aa2678a1373
Autor:
Halyna L. Voskoboinikova, Yevhenii P. Bohuslavskyi, Victoria V. Dovzhuk, Liudmyla V. Konovalova, Natela Sh. Dovzhuk
Publikováno v:
Клінічна та профілактична медицина, Iss 3, Pp 13-20 (2024)
The aim of the article. To study of the incidence of diabetes mellitus in Ukraine and to determine the prospects for the use and pharmaceutical development of antidiabetic drugs. Materials and methods. Data from the State Registers of Medicinal Pr
Externí odkaz:
https://doaj.org/article/77253d51262f4dc78dacdaa5709d0e2f
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-11 (2024)
Abstract Background Modifiable cardiovascular risk factors are high blood pressure, smoking, diabetes, sedentary lifestyle, obesity, and hypercholesterolemia. Aim To investigate the impact of sodium-glucose 2 co-transporter inhibitors (SGLT-2i) on mo
Externí odkaz:
https://doaj.org/article/74ced5615a36419eba2460c48ef3d2bc
Autor:
Laura Lungeanu-Juravle, Mirela Tache, Ana Radu, Carmen Dobjanschi, Petrisor Adamescu, Andra Nica, Emilia Rusu, Gabriela Radulian
Publikováno v:
Romanian Journal of Medical Practice, Vol 19, Iss 1, Pp 30-37 (2024)
Background. Heart failure with preserved ejection fraction is not a single disease but a clinical syndrome secondary to important comorbidities, is increasing in prevalence, and is associated with high functional impairment. This study aimed to compa
Externí odkaz:
https://doaj.org/article/de69e860b69f4edf88ca8e748d0ca032